Dyax Corp. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Apr 24 Calls Today's Calls

Call Details Dyax Corp. Earnings Conference Call (Q1 2008) Thu, Apr 24, 2008, 10:00 am Eastern Listen to the archived event audio About Dyax Corp. (NasdaqGM:DYAX) Dyax Corp., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications. The company uses phage display, a drug discovery technology to identify antibody, small protein, and peptide compounds for clinical development. It offers DX-88, an ecallantide, which is in late stage clinical trial development in two indications. The advanced indication for DX-88 involves the treatment of hereditary angioedema, a life-threatening inflammatory condition, which completed three Phase II trials and one Phase III trial; and the second indication for DX-88 is for the prevention of blood loss during on-pump cardiothoracic surgery (CTS), which completed a Phase I/II trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. It also initiated a Phase II trial for further development of DX-88 in on-pump CTS, including CABG and heart valve replacement or repair procedures. The company also has other biopharmaceutical discovery and development programs, primarily DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, a protease inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. It also provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. The company has co-development programs with CSIRO and Syntonix Pharmaceuticals to discover and develop therapeutic leads; agreements with sanofi-aventis to develop and commercialize DX-2240 as a therapeutic product. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings